Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Serotonergic function in major depression and effect of sertraline and paroxetine treatment
Autore:
Stain-Malmgren, R; El Khoury, A; Aberg-Wistedt, A; Tham, A;
Indirizzi:
St Gorans Hosp, Psychiat Clin, Karolinska Inst, Inst Clin Neurosci,Dept Psychiat, S-11281 Stockholm, Sweden St Gorans Hosp Stockholm Sweden S-11281chiat, S-11281 Stockholm, Sweden
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 16, anno: 2001,
pagine: 93 - 101
SICI:
0268-1315(200103)16:2<93:SFIMDA>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
5-HT UPTAKE SITES; TRITIATED IMIPRAMINE BINDING; H-3 PAROXETINE; RECEPTOR-BINDING; BLOOD-PLATELETS; ANTIDEPRESSANT TREATMENT; ENDOGENOUS-DEPRESSION; SEASONAL-VARIATIONS; SUICIDAL-BEHAVIOR; LIGHT THERAPY;
Keywords:
depression; paroxetine; platelets; serotonin; sertraline;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: El Khoury, A St Gorans Hosp, Psychiat Clin, Karolinska Inst, Inst Clin Neurosci,Dept Psychiat, S-11281 Stockholm, Sweden St Gorans Hosp Stockholm Sweden S-11281 1 Stockholm, Sweden
Citazione:
R. Stain-Malmgren et al., "Serotonergic function in major depression and effect of sertraline and paroxetine treatment", INT CLIN PS, 16(2), 2001, pp. 93-101

Abstract

We investigated platelet [C-14]serotonin (5-HT) uptake and lysergic acid diethylamide [N-methyl-H-3] ([H-3]LSD)- and phenyl-6'-paroxetine ([H-3]paroxetine) binding in 30 patients with major depression at baseline and after 6months of treatment with either paroxetine or sertraline. The study was ofa double-blind design. Baseline data was compared with an age- and gender matched group of healthy volunteers. Baseline V-max was significantly lowerin patients than in controls. B-max for [H-3]paroxetine binding were similar in patients and controls, but patients who suffered their first depression had significantly lower B-max for [H-3]paroxetine binding than patients who had suffered multiple depressions. Twenty-three patients (76%) (13 in the paroxetine group and 10 in the sertraline group) responded to treatment as judged by a 50% or more reduction in Montgomery-Asberg Depression RatingScale (MADRS) scores after 6 months of treatment. There were no significant differences between the paroxetine and sertraline treated groups. Both paroxetine and sertraline caused a significant reduction in V-max and a significant increase in K-m. There was a strong correlation between K-m and:plasma drug concentration in patients who experienced their first depression but not in patients who had suffered multiple episodes. B-max for [H-3]paroxetine binding increased after paroxetine treatment while the opposite occurred after sertraline treatment. There was a significant interaction between the impact of drug and earlier depressions. All patients included in the study had been drug free for at least 2 months. Earlier antidepressant treatment may have long withstanding effects on the serotonin uptake machinery but it cannot be excluded that the sensitivity of the uptake mechanism may become more resistant to change in patients with recurrent depressive episodes. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 01:06:03